These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 20518140)

  • 1. Neurocognitive deficits attributed to androgen deprivation therapy in patients with prostate cancer should be reconsidered.
    Guan X; Lao Y; Bai Y; Wang J; Dong Z
    Int Urol Nephrol; 2024 Jan; 56(1):143-144. PubMed ID: 37707708
    [No Abstract]   [Full Text] [Related]  

  • 2. I'm worried I've been contacted by a predatory publisher - how do I find out?
    Forrester N
    Nature; 2024 May; ():. PubMed ID: 38750201
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 5. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 6. I'm on androgen deprivation therapy (ADT) for prostate cancer. I've heard that it may cause heart problems. Should I be worried?
    Johns Hopkins Med Lett Health After 50; 2010 May; 22(3):8. PubMed ID: 20518140
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.